Clinical Trials Logo

Indolent Non-Hodgkin Lymphoma clinical trials

View clinical trials related to Indolent Non-Hodgkin Lymphoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02483000 Terminated - Clinical trials for Mantle Cell Lymphoma

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Start date: February 1, 2017
Phase: Phase 1
Study type: Interventional

This phase I/II trial studies the side effects and best dose of anti-cluster of differentiation (CD)20 radioimmunotherapy (RIT), and to see how well it works when given before chemotherapy and stem cell transplant in treating patients with B-cell malignancies that have not responded to treatment or have come back after responding to treatment. CD20 is a protein found on the cells of a type of cancer cell called B-cells. Anti-CD20 RIT attaches radioactive material to a drug that is designed to target CD20, which brings radioactive material to the cancer cells to kill the cells. This may kill more tumor cells while causing fewer side effects to healthy tissue. Adding anti-CD20 to standard chemotherapy and stem cell transplant may be more effective in treating patients with B-cell malignancies.

NCT ID: NCT01944943 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia

VISMOLY
Start date: February 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of Vismodegib drug in treatment of patients with relapsed or refractory B-cell lymphoma or chronic lymphocytic leukemia (CLL).